Launching Revvity

A Scientific Solutions Company Powering Innovation from Discovery to Cure - Seite 3

About Revvity

At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2022 revenue of more than $3 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries.

Stay updated by following our Newsroom, LinkedIn, Twitter, YouTube, Facebook and Instagram for updates.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230509005127/en/

The PerkinElmer Stock at the time of publication of the news with a fall of -0,30 % to 116,1USD on Tradegate stock exchange (08. Mai 2023, 22:26 Uhr).